‘Public interest demands easy, affordable access to anti-cancer drug’; Delhi High Court denies interim injunction to Bayer Healthcare for drug ‘Regorafenib’
Bayer healthcare LLC was selling its product of Rs. 36,995 by importing the same into India, whereas the Natco Pharma Ltd. was manufacturing the product in India and selling the same of Rs. 9,900. The injunction was refused due to the huge disparity between the prices offered by both, for a life threatening disease.